{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:46:15Z","timestamp":1791179175608,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T00:00:00Z","timestamp":1377129600000},"content-version":"vor","delay-in-days":568,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Cell"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.ccr.2011.12.020","type":"journal-article","created":{"date-parts":[[2012,2,13]],"date-time":"2012-02-13T09:18:55Z","timestamp":1329124735000},"page":"266-281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":352,"title":["Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with Imatinib"],"prefix":"10.1016","volume":"21","author":[{"given":"Ling","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinwei","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tinisha","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa\u00a0L.","family":"Holyoake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WenYong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccr.2011.12.020_bib1","first-page":"839","article-title":"p53 in chronic myeloid leukemia cell lines","volume":"6","author":"Bi","year":"1992","journal-title":"Leukemia"},{"key":"10.1016\/j.ccr.2011.12.020_bib2","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrm1616","article-title":"Calorie restriction, SIRT1 and metabolism: understanding longevity","volume":"6","author":"Bordone","year":"2005","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ccr.2011.12.020_bib3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrc2562","article-title":"How does SIRT1 affect metabolism, senescence and cancer?","volume":"9","author":"Brooks","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ccr.2011.12.020_bib4","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.cell.2005.08.011","article-title":"Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses","volume":"123","author":"Chen","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.ccr.2011.12.020_bib5","doi-asserted-by":"crossref","first-page":"10794","DOI":"10.1073\/pnas.1934713100","article-title":"Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice","volume":"100","author":"Cheng","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ccr.2011.12.020_bib6","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/blood-2010-12-327437","article-title":"Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment","volume":"118","author":"Chu","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ccr.2011.12.020_bib7","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ccr.2011.12.020_bib8","doi-asserted-by":"crossref","first-page":"7654","DOI":"10.1128\/MCB.24.17.7654-7668.2004","article-title":"Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition","volume":"24","author":"Dai","year":"2004","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.ccr.2011.12.020_bib9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1741-7015-9-99","article-title":"Advances in the treatment of chronic myeloid leukemia","volume":"9","author":"Eiring","year":"2011","journal-title":"BMC Med."},{"key":"10.1016\/j.ccr.2011.12.020_bib10","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-06-0980","article-title":"Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells","volume":"12","author":"Fiskus","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccr.2011.12.020_bib11","doi-asserted-by":"crossref","first-page":"e2020","DOI":"10.1371\/journal.pone.0002020","article-title":"The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth","volume":"3","author":"Firestein","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ccr.2011.12.020_bib12","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.stem.2008.01.002","article-title":"SIRT1 regulates apoptosis and Nanog expression in mouse embryonic stem cells by controlling p53 subcellular localization","volume":"2","author":"Han","year":"2008","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ccr.2011.12.020_bib13","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/sj.leu.2403724","article-title":"Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli","volume":"19","author":"Holtz","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.ccr.2011.12.020_bib14","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1474-9726.2006.00191.x","article-title":"SirT1 fails to affect p53-mediated biological functions","volume":"5","author":"Kamel","year":"2006","journal-title":"Aging Cell"},{"key":"10.1016\/j.ccr.2011.12.020_bib15","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1182\/blood-2005-02-0553","article-title":"MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy","volume":"106","author":"Kojima","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ccr.2011.12.020_bib16","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ccr.2008.03.004","article-title":"Discovery, in\u00a0vivo activity, and mechanism of action of a small-molecule p53 activator","volume":"13","author":"Lain","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccr.2011.12.020_bib17","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1158\/0008-5472.CAN-08-3365","article-title":"The critical role of the class III histone deacetylase SIRT1 in cancer","volume":"69","author":"Liu","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccr.2011.12.020_bib18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.stem.2008.11.006","article-title":"p53 regulates hematopoietic stem cell quiescence","volume":"4","author":"Liu","year":"2009","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ccr.2011.12.020_bib19","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0092-8674(01)00524-4","article-title":"Negative control of p53 by Sir2alpha promotes cell survival under stress","volume":"107","author":"Luo","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.ccr.2011.12.020_bib20","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ccr.2011.12.020_bib21","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1091\/mbc.E07-09-0965","article-title":"SIRT1 acts as a nutrient-sensitive growth suppressor and its loss is associated with increased AMPK and telomerase activity","volume":"19","author":"Narala","year":"2008","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.ccr.2011.12.020_bib22","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1182\/blood-2010-03-273011","article-title":"SIRT1 deficiency compromises mouse embryonic stem cell hematopoietic differentiation, and embryonic and adult hematopoiesis in the mouse","volume":"117","author":"Ou","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ccr.2011.12.020_bib23","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/leu.2011.7","article-title":"p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells","volume":"25","author":"Peterson","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.ccr.2011.12.020_bib24","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0092-8674(01)00619-5","article-title":"Why is p53 acetylated?","volume":"107","author":"Prives","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.ccr.2011.12.020_bib25","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood.V84.8.2391.2391","article-title":"Structure and function of p53 in normal cells and their aberrations in cancer cells: projection on the hematologic cell lineages","volume":"84","author":"Prokocimer","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.ccr.2011.12.020_bib26","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccr.2011.12.020_bib27","doi-asserted-by":"crossref","first-page":"6477","DOI":"10.4049\/jimmunol.174.10.6477","article-title":"Human lymphoid and myeloid cell development in NOD\/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells","volume":"174","author":"Shultz","year":"2005","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ccr.2011.12.020_bib28","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1128\/MCB.26.1.28-38.2006","article-title":"Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage","volume":"26","author":"Solomon","year":"2006","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.ccr.2011.12.020_bib29","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1210\/me.2009-0117","article-title":"MicroRNA 132 regulates nutritional stress-induced chemokine production through repression of SirT1","volume":"23","author":"Strum","year":"2009","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.ccr.2011.12.020_bib30","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.cell.2008.03.025","article-title":"Acetylation is indispensable for p53 activation","volume":"133","author":"Tang","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.ccr.2011.12.020_bib31","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1535-6108(03)00020-5","article-title":"BCR\/ABL activates mdm2 mRNA translation via the La antigen","volume":"3","author":"Trotta","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccr.2011.12.020_bib32","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1126\/science.1092472","article-title":"In\u00a0vivo activation of the p53 pathway by small-molecule antagonists of MDM2","volume":"303","author":"Vassilev","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.ccr.2011.12.020_bib33","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrm2147","article-title":"p53 in health and disease","volume":"8","author":"Vousden","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ccr.2011.12.020_bib34","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ccr.2008.09.001","article-title":"Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice","volume":"14","author":"Wang","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccr.2011.12.020_bib35","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.molcel.2008.09.011","article-title":"Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis","volume":"32","author":"Wang","year":"2008","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ccr.2011.12.020_bib36","doi-asserted-by":"crossref","first-page":"6688","DOI":"10.1073\/pnas.0602030103","article-title":"Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia","volume":"103","author":"Williams","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ccr.2011.12.020_bib37","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccr.2010.03.011","article-title":"Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate","volume":"17","author":"Zhang","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccr.2011.12.020_bib38","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1074\/jbc.M809211200","article-title":"c-Abl phosphorylates Hdmx and regulates its interaction with p53","volume":"284","author":"Zuckerman","year":"2009","journal-title":"J.\u00a0Biol. Chem."}],"container-title":["Cancer Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153561081100482X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153561081100482X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T06:15:04Z","timestamp":1593670504000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153561081100482X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S153561081100482X"],"URL":"https:\/\/doi.org\/10.1016\/j.ccr.2011.12.020","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717952986.793458540","asserted-by":"object"}]},"ISSN":["1535-6108"],"issn-type":[{"value":"1535-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with Imatinib","name":"articletitle","label":"Article Title"},{"value":"Cancer Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccr.2011.12.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}